Correspondence 0001193125-23-230112 from Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310) (TSHA)
Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310)
Date: Sept. 7, 2023 · CIK: 0001806310 · Accession: 0001193125-23-230112
AI Filing Summary & Sentiment
File numbers found in text: 333-274264
Letter
Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive, Suite 1430
Dallas, Texas 75247
September 7,
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
RE: Taysha Gene Therapies, Inc.
Registration Statement on Form S-3
File No. 333-274264
Acceleration Request
Requested Date: September 8, 2023
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-274264) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Friday, September 8, 2023, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones of Cooley LLP, counsel to the Registrant, at (202) 728-7087, or in her absence, Paul Alexander, at (202) 776-2118.
[Signature page follows]
Sincerely,
Taysha Gene Therapies, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 September 7, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama RE: Taysha Gene Therapies, Inc. Registration Statement on Form S-3 File No. 333-274264 Acceleration Request Requested Date: September 8, 2023 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-274264) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Friday, September 8, 2023, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones of Cooley LLP, counsel to the Registrant, at (202) 728-7087, or in her absence, Paul Alexander, at (202) 776-2118. [Signature page follows] Sincerely, Taysha Gene Therapies, Inc. By: /s/ Sean P. Nolan Sean P. Nolan Chief Executive Officer cc: Kamran Alam, Chief Financial Officer, Taysha Gene Therapies, Inc. Madison Jones, Cooley LLP Paul Alexander, Cooley LLP